Literature DB >> 8339260

Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues.

N Albin1, L Massaad, C Toussaint, M C Mathieu, J Morizet, O Parise, A Gouyette, G G Chabot.   

Abstract

In an attempt to better understand breast tumors sensitivity or resistance to anticancer drugs, the main drug-metabolizing enzyme systems were evaluated in both breast tumors and their corresponding peritumoral tissues in 12 patients. The following enzymes were assayed by Western blot: cytochromes P-450 (1A1/A2, 2B1/B2, 2C8-10, 2E1, 3A4); glutathione S-transferases (GST-alpha, -mu, and -pi); and epoxide hydrolase. The activity of the following enzymes or cofactor were determined by spectrophotometric or fluorometric assays: GST; total glutathione; UDP-glucuronosyltransferase; beta-glucuronidase; sulfotransferase; and sulfatase. Results showed the absence of all probed cytochromes P-450 in both tumoral and peritumoral tissues. GST activity was significantly (P < 0.05) higher in tumors (mean +/- SD, 399 +/- 362 nmol/min/mg) than in corresponding peritumoral tissues (86 +/- 67). The GST isoenzymes GST-mu and GST-pi (determined by immunoblotting) were also higher in tumors than in corresponding peritumoral tissues (3- and 5-fold, respectively). Both GST-mu and GST-pi levels were significantly correlated with GST activity. GST-alpha was not detected in either tumoral or peritumoral tissues. Glutathione levels in tumors (22 +/- 23 nmol/mg protein) were not statistically different from peritumoral tissues (11 +/- 12). Epoxide hydrolase was expressed at similar levels in tumors and peritumoral tissues. The glucuronide-forming enzyme UDP-glucuronosyltransferase was 5-fold lower in tumors (0.1 +/- 0.2 nmol/h/mg) than in peritumoral tissues (0.5 +/- 1), whereas the opposite was observed for the hydrolytic enzyme beta-glucuronidase, which was 6-fold higher in tumors (736 +/- 1392 nmol/h/mg) compared to peritumoral tissues (125 +/- 75). No difference was noted between tumoral and peritumoral tissues for sulfotransferase (1 +/- 2 nmol/h/mg), but the corresponding hydrolytic enzyme (sulfatase) was 2-fold higher in tumoral tissues (14 +/- 15 nmol/h/mg) than in peritumoral tissues (6 +/- 2). In conclusion, several differences were observed between human breast tumors and peritumoral tissues for many conjugating enzymes (GST-mu, GST-pi, and UDP-glucuronosyltransferase) and hydrolytic enzymes (sulfatase and beta-glucuronidase). These noteworthy differences between tumoral and peritumoral tissues with regard to their main drug-metabolizing enzymes could play a role in the relative drug sensitivity or insensitivity of human breast cancer tissues to chemotherapeutic agents and could be potential targets for chemotherapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8339260

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

Review 1.  Optimising the delivery of tubulin targeting agents through antibody conjugation.

Authors:  Gary D Stack; John J Walsh
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

2.  Disposition of hop prenylflavonoids in human breast tissue.

Authors:  Selin Bolca; Jinghu Li; Dejan Nikolic; Nathalie Roche; Phillip Blondeel; Sam Possemiers; Denis De Keukeleire; Marc Bracke; Arne Heyerick; Richard B van Breemen; Herman Depypere
Journal:  Mol Nutr Food Res       Date:  2010-07       Impact factor: 5.914

3.  CYP3A4 overexpression enhances the cytotoxicity of the antitumor triazoloacridinone derivative C-1305 in CHO cells.

Authors:  Ewa Augustin; Barbara Borowa-Mazgaj; Agnieszka Kikulska; Milena Kordalewska; Monika Pawłowska
Journal:  Acta Pharmacol Sin       Date:  2012-11-19       Impact factor: 6.150

Review 4.  Understanding breast cancer risk -- where do we stand in 2005?

Authors:  R G Dumitrescu; I Cotarla
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

5.  Role of metabolism in the effects of genistein and its phase II conjugates on the growth of human breast cell lines.

Authors:  Bo Yuan; Linglan Wang; Yi Jin; Huijuan Zhen; Pingwei Xu; Youjun Xu; Chibing Li; Haiyan Xu
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

6.  Involvement of AP-2 binding sites in regulation of human beta-glucuronidase.

Authors:  Christiane Kunert-Keil; Bernhard Sperker; Sandra Bien; Gabriele Wolf; Markus Grube; Heyo K Kroemer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-10-28       Impact factor: 3.000

Review 7.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

Review 8.  Glutathione levels in human tumors.

Authors:  Michael P Gamcsik; Mohit S Kasibhatla; Stephanie D Teeter; O Michael Colvin
Journal:  Biomarkers       Date:  2012-08-20       Impact factor: 2.658

Review 9.  Does glutathione S-transferase Pi (GST-Pi) a marker protein for cancer?

Authors:  S Aliya; P Reddanna; K Thyagaraju
Journal:  Mol Cell Biochem       Date:  2003-11       Impact factor: 3.396

10.  Anti-tumour activity and toxicity of the new prodrug 9-aminocamptothecin glucuronide (9ACG) in mice.

Authors:  Z M Prijovich; B-M Chen; Y-L Leu; J-W Chern; S R Roffler
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.